Vista Pharmaceuticals Reports Widened Quarterly Loss, Reappoints Key Executives
Vista Pharmaceuticals Limited reported a net loss of Rs. 129.04 crore for Q1 FY2026, compared to Rs. 85.70 crore loss in Q1 FY2025. Revenue declined 15.4% to Rs. 151.88 crore. The company reappointed three key executives - Mr. Murali Meraga as Managing Director, Mr. Pavan Sathvik Gilaka and Mr. Dhananjaya Alli as Whole-time Directors for three-year terms. The 34th AGM is scheduled for September 30, 2025, via video conferencing. Book closure dates are set from September 24 to 30, 2025.
*this image is generated using AI for illustrative purposes only.
Vista Pharmaceuticals Limited, a pharmaceutical manufacturing company, has reported a wider net loss for the quarter ended June 30, 2025, amid declining revenue. The company also announced the reappointment of key executives and scheduled its Annual General Meeting.
Financial Performance
Vista Pharmaceuticals reported a net loss of Rs. 129.04 crore for the quarter ended June 30, 2025, compared to a loss of Rs. 85.70 crore in the same quarter last year. The company's revenue declined to Rs. 151.88 crore from Rs. 179.50 crore year-over-year, representing a 15.4% decrease.
The company's financial results for the quarter are summarized in the table below:
| Particulars (Rs. in Lakhs) | Q1 FY2026 (June 30, 2025) | Q1 FY2025 (June 30, 2024) |
|---|---|---|
| Revenue from operations | 151.88 | 179.50 |
| Total Expenses | 299.88 | 303.78 |
| Profit/(Loss) before tax | (148.01) | (117.13) |
| Net Profit/(Loss) | (129.04) | (85.70) |
Corporate Updates
The Board of Directors of Vista Pharmaceuticals has approved several key corporate actions:
Reappointment of Directors: The board recommended the reappointment of two directors retiring by rotation - Mr. Umakanth Katta and Mr. Divakar Reddy Yerrabommanahalli.
Executive Reappointments: The company approved the reappointment of three key executives for three-year terms starting October 19, 2025, subject to shareholder approval:
- Mr. Murali Meraga as Managing Director
- Mr. Pavan Sathvik Gilaka as Whole-time Director
- Mr. Dhananjaya Alli as Whole-time Director
Annual General Meeting: The 34th Annual General Meeting (AGM) is scheduled for September 30, 2025, to be conducted through video conferencing.
Book Closure: The Register of Members and Share Transfer Books will remain closed from September 24 to September 30, 2025 (both days inclusive).
Management Profiles
- Mr. Murali Meraga: Holds a B. Tech in Technology with extensive experience in Marketing, Administration, Finance, and Foreign Exchange management.
- Mr. Pavan Sathvik Gilaka: Possesses a Bachelor's degree in Business Administration (BBA) with professional experience in Human Resources, Marketing, and Administration.
- Dr. Dhananjaya Alli: A Promoter & Director of Vista Pharmaceuticals, holds a Ph.D. and M.S. in Pharmaceutical Sciences, playing a key role in the company's growth through research-driven strategies.
The company's Board of Directors has affirmed that none of the reappointed directors are debarred from holding office by any SEBI order or other authority.
Vista Pharmaceuticals continues to focus on its core business of manufacturing pharmaceutical products, as noted in its segment reporting.
Historical Stock Returns for Vista Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.74% | -0.93% | -0.31% | -8.71% | -24.29% | +14.94% |
18
